Alice Motion

Last updated

Alice Motion
Alice Motion (cropped).jpg
Motion in October 2022
Born
Alice Elizabeth Williamson

(1984-10-28) 28 October 1984 (age 38)
NationalityBritish
Alma mater
Scientific career
Fields
Institutions University of Sydney
Doctoral advisor Matthew J. Gaunt
Other academic advisors
Website www.alicemotion.com

Alice Elizabeth Motion (born Alice Williamson, [1] 28 October 1984) is a British chemist, science communicator, and associate professor at the School of Chemistry, University of Sydney. [2] She is the founder of the Breaking Good project which encourages high school and undergraduate students to take part in research that can benefit human health. [3] In 2018, the Breaking Good project was a finalist on the Google.org Impact Challenge. [4]

Contents

Education

Motion received her MChem from the University of Leeds in 2007 where she worked with Philip Kocienski on the synthesis of an N-acetylcolchinol-combretastatin hybrid. She moved to the University of Cambridge where she obtained her PhD in 2012 while working with Matthew J. Gaunt on strategies for asymmetric arylation. [5]

Career

In 2012, Motion moved to the University of Sydney in Australia to work with Matthew H. Todd on the Open Source Malaria project as Postdoctoral Research Fellow. [6] In 2014, she became a Postdoctoral Teaching Fellow at the same institution until her promotion to Lecturer in Chemical Education and Outreach at the same institution in 2017.

Pyrimethamine is a pharmaceutical medicine used in combination with leucovorin to treat toxoplasmosis and cystoisosporiasis and in combination with dapsone to prevent Pneumocystis jiroveci pneumonia in HIV/AIDS patients. [7] [8] In 2015, Turing Pharmaceuticals drastically increased the price of pyrimethamine, which it markets as Daraprim, from about US$13.50 to $750 per tablet. [9] [10] In response, Motion, along with her academic advisor, Matthew H. Todd, and the Open Source Malaria team led a small team of high school students from Sydney Grammar School to synthesise the drug. [11] [12] The team produced 3.7 grams of pyrimethamine for under US$20, which would be worth between $US35,000 and $US110,000 in the United States according to Turing Pharmaceuticals's pricing. [13] This received significant media attention and was featured in The Guardian [12] and Time magazine, [14] and on ABC News (Australia), [13] the BBC, [15] and CNN. [16]

Motion, like her former research advisor, is a proponent of open science. [17] [18] [19] [20] [21] She believes that open science and research provides transparency of data and results that prevent unnecessary duplication. [22]

In December 2022 Motion was appointed interim director of Sydney Nano. [23]

Honours and awards

See also

Related Research Articles

<span class="mw-page-title-main">Toxoplasmosis</span> Protozoan parasitic disease

Toxoplasmosis is a parasitic disease caused by Toxoplasma gondii, an apicomplexan. Infections with toxoplasmosis are associated with a variety of neuropsychiatric and behavioral conditions. Occasionally, people may have a few weeks or months of mild, flu-like illness such as muscle aches and tender lymph nodes. In a small number of people, eye problems may develop. In those with a weak immune system, severe symptoms such as seizures and poor coordination may occur. If a person becomes infected during pregnancy, a condition known as congenital toxoplasmosis may affect the child.

<span class="mw-page-title-main">Sydney Grammar School</span> Grammar school in Sydney, Australia

Sydney Grammar School is an independent, fee-paying, non-denominational day school for boys, located in Sydney, Australia.

<span class="mw-page-title-main">Artesunate</span> Chemical compound

Artesunate (AS) is a medication used to treat malaria. The intravenous form is preferred to quinine for severe malaria. Often it is used as part of combination therapy, such as artesunate plus mefloquine. It is not used for the prevention of malaria. Artesunate can be given by injection into a vein, injection into a muscle, by mouth, and by rectum.

<span class="mw-page-title-main">Pyrimethamine</span> Medication

Pyrimethamine, sold under the brand name Daraprim among others, is a medication used with leucovorin to treat the parasitic diseases toxoplasmosis and cystoisosporiasis. It is also used with dapsone as a second-line option to prevent Pneumocystis jiroveci pneumonia in people with HIV/AIDS. It was previously used for malaria but is no longer recommended due to resistance. Pyrimethamine is taken by mouth.

<span class="mw-page-title-main">Sulfadiazine</span> Chemical compound

Sulfadiazine is an antibiotic. Used together with pyrimethamine, a dihydrofolate reductase inhibitor, it is the treatment of choice for toxoplasmosis, which is caused by a protozoan parasite. It is a second-line treatment for otitis media, prophylaxis of rheumatic fever, chancroid, chlamydia, and infections by Haemophilus influenzae. It is also used as adjunct therapy for chloroquine-resistant malaria and several forms of bacterial meningitis. It is taken by mouth. Sulfadiazine is available in multiple generic tablets of 500 mg. For urinary tract infections, the usual dose is 4 to 6 grams daily in 3 to 6 divided doses.

<span class="mw-page-title-main">Amodiaquine</span> Chemical compound

Amodiaquine (ADQ) is a medication used to treat malaria, including Plasmodium falciparum malaria when uncomplicated. It is recommended to be given with artesunate to reduce the risk of resistance. Due to the risk of rare but serious side effects, it is not generally recommended to prevent malaria. Though, the WHO in 2013 recommended use for seasonal preventive in children at high risk in combination with sulfadoxine and pyrimethamine.

Medication costs, also known as drug costs are a common health care cost for many people and health care systems. Prescription costs are the costs to the end consumer. Medication costs are influenced by multiple factors such as patents, stakeholder influence, and marketing expenses. A number of countries including Canada, parts of Europe, and Brazil use external reference pricing as a means to compare drug prices and to determine a base price for a particular medication. Other countries use pharmacoeconomics, which looks at the cost/benefit of a product in terms of quality of life, alternative treatments, and cost reduction or avoidance in other parts of the health care system. Structures like the UK's National Institute for Health and Clinical Excellence and to a lesser extent Canada's Common Drug Review evaluate products in this way.

Open-notebook science is the practice of making the entire primary record of a research project publicly available online as it is recorded. This involves placing the personal, or laboratory, notebook of the researcher online along with all raw and processed data, and any associated material, as this material is generated. The approach may be summed up by the slogan 'no insider information'. It is the logical extreme of transparent approaches to research and explicitly includes the making available of failed, less significant, and otherwise unpublished experiments; so called 'dark data'. The practice of open notebook science, although not the norm in the academic community, has gained significant recent attention in the research and general media as part of a general trend towards more open approaches in research practice and publishing. Open notebook science can therefore be described as part of a wider open science movement that includes the advocacy and adoption of open access publication, open data, crowdsourcing data, and citizen science. It is inspired in part by the success of open-source software and draws on many of its ideas.

Medicines for Malaria Venture (MMV), a not-for-profit public-private partnership, was established as a foundation in Switzerland in 1999. Its mission is to reduce the burden of malaria in disease-endemic countries by developing and facilitating the delivery of antimalarial drugs. Its vision is a world in which these innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and help to ultimately eradicate the disease.

The School of Chemistry, University of Sydney is a school of the Faculty of Science at the University of Sydney.

Sulfadoxine/pyrimethamine, sold under the brand name Fansidar, is a combination medication used to treat malaria. It contains sulfadoxine and pyrimethamine. For the treatment of malaria it is typically used along with other antimalarial medication such as artesunate. In areas of Africa with moderate to high rates of malaria, three doses are recommended during the second and third trimester of pregnancy.

<span class="mw-page-title-main">Martin Shkreli</span> American businessman and convicted felon

Martin Shkreli is an American businessman, CEO, and hedge fund manager convicted on Federal fraud charges connected to his businesses. Shkreli is the co-founder of the hedge funds Elea Capital, MSMB Capital Management, and MSMB Healthcare, the co-founder and former CEO of pharmaceutical firms Retrophin and Turing Pharmaceuticals, and the former CEO of start-up software company Gödel Systems, which he founded in August 2016.

<i>Once Upon a Time in Shaolin</i> Album by Wu-Tang Clan

Once Upon a Time in Shaolin is the seventh studio album by the American hip hop group Wu-Tang Clan. Only one physical copy of the album was created, with no ability to download or stream it digitally. Purchased directly from the Wu-Tang Clan in 2015, it became the most expensive work of music ever sold.

<span class="mw-page-title-main">Vyera Pharmaceuticals</span> Pharmaceutical company

Vyera Pharmaceuticals is a pharmaceutical company incorporated in Zug, Switzerland, with offices in New York City. The company started to do business in the US as Vyera Pharmaceuticals in September 2017.

Harrow Health, formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, TN.

Colin Llewellyn Raston is a Professor of Chemistry of Flinders University in Adelaide, South Australia and the Premier's Professorial Fellow in Clean Technology. In 2015, he was awarded an Ig Nobel Prize in "for inventing a chemical recipe to partially un-boil an egg". In 2016, Raston was made an Officer of the Order of Australia for his services to science.

<span class="mw-page-title-main">Four Thieves Vinegar Collective</span> Anarchist biohacking group

The Four Thieves Vinegar Collective is an anarchist biohacking group founded in 2015 by Michael Laufer. They have published instructions for the "EpiPencil", an epinephrine autoinjector, and the "Apothecary MicroLab", a do-it-yourself (DIY) device intended to make a variety of medications, most notably pyrimethamine (Daraprim). They have been criticized by the medical community for causing potential harm to patients with the DIY instructions, but Laufer claims to defend people's right to attempt their own medical treatment.

Peter Jonathan Rutledge is a New Zealand chemist and professor at the School of Chemistry, University of Sydney. His research has focused on drug development for tuberculosis, antibiotics, and metal sensing. He has engaged in some research activity on catalysis.

<span class="mw-page-title-main">Adaora Adimora</span> Professor of Medicine and epidemiology

Adaora Alise Adimora is an American doctor and academic. She is the Sarah Graham Kenan Distinguished Professor of Medicine and professor of epidemiology at the University of North Carolina School of Medicine. Her research centers on the transmission of HIV, as well as other sexually transmitted infections (STIs), among minority populations. Her work has highlighted the importance of social determinants of HIV transmission and the need for structural interventions to reduce risk. In 2019, she became an elected member of the National Academy of Medicine in recognition of her contributions.

<span class="mw-page-title-main">Matthew Todd (chemist)</span> British chemist (born 1973)

Matthew Houghton Todd is a British chemist and the Professor and Chair of Drug Discovery of the School of Pharmacy at University College London. He is the founder of Open Source Malaria (OSM) and his research focuses on drug discovery and development for this disease. Recently, he has expanded to other areas, particularly neglected diseases such as tuberculosis and mycetoma in the Open Source Tuberculosis (OSTB) and Open Source Mycetoma (MycetOS) project, through a collaboration with the Drugs for Neglected Diseases Initiative and Erasmus MC. In addition, he has some research activity in catalysis and methodology.

References

  1. Hobbs, Bernie (22 July 2020). "We need to open science up to everyone". ABC Radio National. Retrieved 3 December 2020.
  2. "Dr Alice Motion". sydney.edu.au. The University of Sydney . Retrieved 24 April 2019.
  3. "Breaking Good". Breaking Good Project. Retrieved 24 April 2019.
  4. "Google.org Impact Challenge Australia 2018". 2018. Retrieved 24 April 2019.
  5. Bigot, Aurélien; Williamson, Alice E.; Gaunt, Matthew J. (2011). "Enantioselective α-Arylation of N-Acyloxazolidinones with Copper(II)-bisoxazoline Catalysts and Diaryliodonium Salts". Journal of the American Chemical Society . 133 (35): 13778–13781. doi:10.1021/ja206047h. PMID   21848264. S2CID   2409722.
  6. Williamson, Alice E.; Todd, Matthew H.; et al. (2016). "Open Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos Arylpyrroles". ACS Central Science. 2 (10): 687–701. doi:10.1021/acscentsci.6b00086. PMC   5084075 . PMID   27800551.
  7. "Pyrimethamine". Drugs.com . 5 March 2019. Archived from the original on 26 April 2019. Retrieved 26 April 2019.
  8. Hamilton, Richard J. (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition (16th ed.). Jones & Bartlett Learning. p. 54. ISBN   9781284057560.
  9. Timmerman, Luke (23 September 2015). "A Timeline of the Turing Pharma Controversy". Forbes . Archived from the original on 21 November 2018. Retrieved 26 April 2019.
  10. Pollack, Andrew (24 November 2015). "Turing Refuses to Lower List Price of Toxoplasmosis Drug". The New York Times . Archived from the original on 26 April 2019. Retrieved 26 April 2019.
  11. Reiner, Vivienne (30 November 2016). "Students make $750 drug cheaply with Open Source Malaria team". The University of Sydney . Retrieved 13 February 2019.
  12. 1 2 Davey, Melissa (1 December 2016). "Australian students recreate Martin Shkreli price-hike drug in school lab". The Guardian . Retrieved 12 February 2019.
  13. 1 2 Hunjan, Raveen (30 November 2016). "Daraprim drug's key ingredient recreated by high school students in Sydney for just $20". Australian Broadcasting Corporation . ABC News . Retrieved 12 February 2019.
  14. Lui, Kevin (2 December 2016). "Watch Martin Shkreli Respond to the School Kids Who Recreated His Drug for $2 a Dose". Time . Retrieved 23 April 2019.
  15. Dunlop, Greg (1 December 2016). "Martin Shkreli: Australian boys recreate life-saving drug". BBC News . Retrieved 12 February 2019.
  16. Roberts, Elizabeth (1 December 2016). "'Pharma Bro' Martin Shkreli meets his match in a group of Australian schoolboys". CNN . Retrieved 12 February 2019.
  17. Williamson, Alice (29 June 2015). "Open science: the future of research?". ABC News . Australian Broadcasting Corporation . Retrieved 24 April 2019.
  18. Todd, Matthew H.; Wells, Timothy N. C.; Olliaro, Piero; Willis, Paul; Badiola, Katrina A.; Robins, Michael; Woelfle, Michael; Williamson, Alice E.; Ylioja, Paul M.; Robertson, Murray N. (2013). "Open source drug discovery – A limited tutorial". Parasitology . 141 (1): 148–157. doi:10.1017/S0031182013001121. ISSN   0031-1820. PMC   3884843 . PMID   23985301.
  19. Stevens, Katherine (4 October 2016). "Open-source science to enable drug discovery". ACS Axial. American Chemical Society . Retrieved 24 April 2019.
  20. Williamson, Alice (10 June 2014). "International team of scientists open sources search for malaria cure". Opensource.com . Retrieved 24 April 2019.
  21. Williamson, Alice; Todd, Matthew (14 September 2016). "Making drug development less secretive could lead to quicker, cheaper therapies". The Conversation . Retrieved 24 April 2019.
  22. Williamson, Alice (4 October 2017). "Open science – to benefit all" (Presentation to the Royal Institution of Great Britain). Rebroadcast by Paul Barclay (presenter) on Radio National's Big Ideas programme on 31 January 2018. Retrieved 24 April 2019 – via Australian Broadcasting Corporation.
  23. "Alice Motion appointed interim Sydney Nano Director". The University of Sydney. Retrieved 8 December 2022.
  24. Zukerman, Wendy (7 March 2015). "Top 5 Under 40 winners announced". Radio National . Australian Broadcasting Corporation . Retrieved 24 April 2019.
  25. "RACI Nyholm Youth Lecture Series". raci.org.au. Royal Australian Chemical Institute. 2019. Retrieved 26 April 2019.
  26. "2020 Australian Museum Eureka Prize winners". The Australian Museum. Archived from the original on 24 November 2020. Retrieved 9 December 2020.